Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More
Xconomy
SEPTEMBER 30, 2016
Who will be first to market with a new type of cancer treatment known as CAR-T? Who will break free of the pack of companies developing drugs meant to prevent migraines? —Sarepta inked a research pact with Catabasis Pharmaceuticals (NASDAQ: CATB ) to develop a combination therapy for Duchenne. TheStreet.com has more here.
Let's personalize your content